Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a specific electric pulse speed up bell palsy healing?

NCT ID NCT06063954

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two different electroacupuncture waveforms (continuous vs. intermittent) in 120 adults with Bell palsy, a condition causing sudden facial weakness. Participants had moderate to severe symptoms and had already taken standard steroid treatment. The goal was to see which waveform better improves facial nerve function and quality of life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

120 people

The number who actually took part.

Started

Nov 2023

Finished

May 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Diagnosed as BP by specialist. 2. The score of FNGS 2.0 ≥ 15 at the day 21 since the onset of BP. 3. 18 years ≤ age ≤ 65 years. 4. Received prednisolone within 72 hours since initial symptoms of BP, the prednisolone dose used was 60 mg per day for 5 days and then reduced by 10 mg per day. 5. Signed informed consent and volunteered to participate in this study. Exclusion Criteria: 1. Facial palsy caused by other diseases or injury. 2. Ramsey-Hunt syndrome. 3. Bilateral facial palsy. 4. History of previous facial palsy. 5. Manifesting facial spasm, facial synkinesis or contracture at day 21 since the onset of BP. 6. History of surgery on face. 7. Combined with uncontrolled diabetes mellitus, uncontrolled hypertension, serious heart, liver, kidney damage or cognitive impairment, aphasia, mental disorders. 8. Installing pacemakers. 9. Pregnant and lactating patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bell palsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hangzhou First People' s Hospital, Hangzhou

    Hangzhou, Zhejing, 310006, China

  • The First Affiliated Hospital of Zhejiang Chinese Medical University

    Hangzhou, Zhejiang, 310006, China

  • The Third Affiliated hospital of Zhejiang Chinese Medical University

    Hangzhou, Zhejiang, 310053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.